Bauman, J. E., Licitra, L. F., Keam, B., Bauman, J. R., Lin, V. T. G., Akhave, N., Fayette, J., Neupane, P. C., Soudy, H., Cho, B. C., Chung, C. H., Saba, N. F., Wong, D. J., Harrington, K. J., Tourneau, C. L., Muggeo, S., Jin, B., Lebedinsky, C., Braendle, E. E., Haddad, R. I. (2025). FIERCE-HN: A multicenter, randomized, double-blind, placebo-controlled, phase 3 study of ficlatuzumab (HGF/cMET MAb) in combination with cetuximab in participants with recurrent or metastatic (R/M) HPV negative head and neck squamous cell carcinoma (HNSCC).. Journal of Clinical Oncology. https://doi.org/10.1200/jco.2025.43.16_suppl.tps6115